Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-06-03 17:35 |
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infe…
|
English | 159.8 KB | ||
| 2024-05-31 17:35 |
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le mar…
|
French | 218.4 KB | ||
| 2024-05-31 17:35 |
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
|
English | 212.4 KB | ||
| 2024-05-21 07:00 |
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
|
English | 195.3 KB | ||
| 2024-05-21 07:00 |
Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur …
|
French | 166.3 KB | ||
| 2024-05-13 07:00 |
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Si…
|
English | 174.5 KB | ||
| 2024-05-13 07:00 |
Valneva annonce de nouveaux résultats positifs chez les adolescents pour l’étud…
|
French | 245.3 KB | ||
| 2024-05-07 07:00 |
Valneva publie ses résultats financiers du premier trimestre 2024 et fait un po…
|
French | 284.1 KB | ||
| 2024-05-07 07:00 |
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Up…
|
English | 242.6 KB | ||
| 2024-05-06 07:30 |
Déclaration d’actions et de droits de vote - 30 avril 2024 - Valneva SE
|
French | 156.9 KB | ||
| 2024-05-06 07:30 |
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
|
English | 47.5 KB | ||
| 2024-04-12 14:34 |
Franchissement de seuil
|
French | 268.0 KB | ||
| 2024-04-04 18:00 |
Déclaration d'actions et de droits de vote de la société Valneva SE - mars 2024
|
French | 158.0 KB | ||
| 2024-04-04 18:00 |
Declaration of voting rights - Valneva SE, March 2024
|
English | 47.6 KB | ||
| 2024-03-26 07:00 |
Valneva lance un essai de Phase 1 sur son candidat vaccin de deuxième génératio…
|
French | 123.1 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
